"This analysis explores the critical shifts in the sector, highlighting a projected growth trajectory driven by technological integration and changing consumer dynamics."

According to analysts at Vantage Market Research, the United States Clinical Trial Supply and Logistics Market size is worth USD 2.91 Billion in 2025 and is projected to reach USD 6.98 Billion by 2035, growing at a CAGR (Compound Annual Growth Rate) of 9.15% from 2026 to 2035. Key trends include AI-enabled inventory forecasting, decentralized clinical trials, direct-to-patient distribution, advanced cold-chain logistics, IoT-enabled shipment monitoring, cloud-based supply orchestration, cryogenic transportation, integrated depot networks, and increasing demand for end-to-end clinical supply visibility.

United States Clinical Trial Supply and Logistics Market Overview

The United States Clinical Trial Supply and Logistics Market is becoming an increasingly strategic component of modern clinical development as pharmaceutical and biotechnology companies manage more complex research programs, geographically dispersed trial networks, advanced therapies, and patient-centric study models. Clinical trial supply and logistics encompasses supply planning, clinical packaging, labeling, comparator sourcing, warehousing, temperature-controlled transportation, depot management, site distribution, direct-to-patient delivery, product returns, and compliant destruction.

The increasing complexity of clinical trials is changing procurement requirements across the pharmaceutical and biotechnology industries. Sponsors are increasingly seeking logistics providers that can coordinate inventory forecasting, packaging, labeling, transportation, depot operations, and real-time shipment monitoring through integrated platforms. Rather than treating logistics as an isolated transportation activity, organizations are increasingly incorporating clinical supply management into broader trial execution strategies.

The expansion of decentralized and hybrid clinical trials is another important factor shaping the market. Direct-to-patient distribution allows investigational products to reach participants outside traditional clinical sites, supporting remote participation and patient-centric research models. This approach requires sophisticated delivery coordination, patient scheduling, temperature monitoring, validated processes, and reliable communication between sponsors, logistics providers, healthcare professionals, and participants.

Advanced therapies are also increasing the technical requirements of clinical supply chains. Biologics, cell therapies, gene therapies, and other temperature-sensitive investigational products require specialized packaging, cold storage, continuous environmental monitoring, and validated transportation procedures. Cryogenic logistics is becoming particularly relevant for therapies requiring ultra-low-temperature preservation and stringent chain-of-identity controls.

Overall, the United States Clinical Trial Supply and Logistics Market is evolving toward integrated, technology-enabled supply ecosystems that combine clinical supply planning, digital visibility, specialized transportation, regulatory compliance, and patient-centric distribution.

DHL Group Strengthened Healthcare Logistics Capabilities for Temperature-Sensitive Clinical Supply Chains

2025–2026 — DHL Group continued expanding its healthcare logistics infrastructure and temperature-controlled capabilities to support increasingly complex pharmaceutical, biologics, and clinical supply requirements.

Key Takeaways from the Report

Increasing complexity of clinical trials is accelerating demand for integrated supply planning, inventory management, packaging, and distribution services.
Decentralized and hybrid clinical trials are increasing adoption of direct-to-patient logistics models and patient-centric delivery infrastructure.
Clinical Trial Supply Management remains the leading service category because of its role in forecasting, inventory planning, replenishment, and end-to-end supply coordination.
Cold Chain Logistics is expanding as biologics, advanced therapies, personalized medicines, and temperature-sensitive investigational products become more prominent in clinical development pipelines.
AI-enabled forecasting and predictive analytics are improving inventory allocation, demand planning, exception management, and operational decision-making.
IoT-enabled sensors and real-time shipment monitoring are strengthening temperature visibility and product integrity throughout transportation.
Cryogenic logistics is gaining importance as cell and gene therapy programs require specialized ultra-low-temperature transportation and storage capabilities.
Pharmaceutical companies remain major users of clinical supply and logistics services because of their extensive clinical development portfolios and multinational research programs.
Biotechnology companies are increasingly outsourcing logistics functions to specialized providers to access scalable infrastructure, regulatory expertise, and flexible service models.
Direct-to-patient distribution is reshaping traditional clinical supply networks by supporting remote participation, home-based treatment, and decentralized research.
Digital interoperability between clinical trial management systems, warehouse platforms, transportation systems, and enterprise software is becoming increasingly important for end-to-end supply visibility.
Integrated logistics providers with specialized cold-chain infrastructure, global depot networks, digital platforms, and regulatory expertise are increasingly positioned to support complex clinical development programs.

Top Players

Thermo Fisher Scientific Inc.
UPS Healthcare
DHL Group
Marken
World Courier
Almac Group
PCI Pharma Services
Parexel International
Catalent, Inc.
Movianto
Sharp Services
KLIFO
Myonex
Ancillare LP
Fisher Clinical Services

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional and industry-specific market landscapes, and evaluate the impact of major developments affecting pharmaceutical research and clinical development. Additionally, our reports feature a detailed competitive landscape, including company profiles, strategic developments, technology capabilities, and service positioning, providing actionable intelligence to support business strategies.

Latest Announcement

April 2026 — Marken expanded its decentralized clinical trial logistics capabilities with enhanced direct-to-patient distribution services, supporting the growing requirement for patient-centric clinical supply models and remote trial participation.